AngioDynamics (NASDAQ:ANGO) Stock Price Target Cut by HC Wainwright

AngioDynamics (NASDAQ:ANGO) had its price target dropped by research analysts at HC Wainwright from $19.00 to $18.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. HC Wainwright’s target price points to a potential upside of 69.16% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 target price on shares of AngioDynamics in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

AngioDynamics Stock Down 6.7%

Shares of NASDAQ:ANGO traded down $0.76 during trading on Tuesday, hitting $10.64. 529,714 shares of the company traded hands, compared to its average volume of 509,442. The stock has a market capitalization of $447.50 million, a price-to-earnings ratio of -13.65 and a beta of 0.30. The business’s fifty day moving average is $15.25 and its 200-day moving average is $13.13. AngioDynamics has a one year low of $9.39 and a one year high of $16.29.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $80.92 million during the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts forecast that AngioDynamics will post -0.25 EPS for the current year.

Insider Activity

In related news, SVP Warren Jr sold 23,370 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently bought and sold shares of ANGO. Integrated Wealth Concepts LLC acquired a new stake in AngioDynamics during the second quarter valued at approximately $38,000. Corient Private Wealth LP purchased a new position in AngioDynamics in the 2nd quarter worth about $134,000. Public Employees Retirement System of Ohio purchased a new stake in shares of AngioDynamics in the 2nd quarter valued at approximately $64,000. Bank of America Corp DE acquired a new stake in shares of AngioDynamics in the second quarter worth $4,490,000. Finally, Gallagher Fiduciary Advisors LLC purchased a new position in shares of AngioDynamics during the second quarter valued at $589,000. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.